CN106176883A - 肠道细菌群落构成比例调节剂 - Google Patents
肠道细菌群落构成比例调节剂 Download PDFInfo
- Publication number
- CN106176883A CN106176883A CN201610580273.7A CN201610580273A CN106176883A CN 106176883 A CN106176883 A CN 106176883A CN 201610580273 A CN201610580273 A CN 201610580273A CN 106176883 A CN106176883 A CN 106176883A
- Authority
- CN
- China
- Prior art keywords
- willd
- extract
- salacia
- salacia prinoides
- platymiscium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 68
- 230000001105 regulatory effect Effects 0.000 title abstract description 46
- 230000000694 effects Effects 0.000 claims abstract description 41
- 230000001629 suppression Effects 0.000 claims abstract description 22
- 244000087020 Salacia prinoides Species 0.000 claims description 54
- 239000000284 extract Substances 0.000 claims description 50
- 241000605059 Bacteroidetes Species 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241000192125 Firmicutes Species 0.000 claims description 18
- 241000196324 Embryophyta Species 0.000 claims description 15
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 10
- 235000011073 invertase Nutrition 0.000 claims description 10
- 241000647991 Salacia reticulata Species 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 241001529246 Platymiscium Species 0.000 claims 16
- 230000000994 depressogenic effect Effects 0.000 claims 5
- 229940124024 weight reducing agent Drugs 0.000 claims 5
- 239000013585 weight reducing agent Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 235000019786 weight gain Nutrition 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 50
- 239000000463 material Substances 0.000 abstract description 37
- 235000013305 food Nutrition 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 18
- 230000000844 anti-bacterial effect Effects 0.000 description 17
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 14
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 11
- 108010028144 alpha-Glucosidases Proteins 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 10
- 235000005487 catechin Nutrition 0.000 description 10
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 10
- 239000011651 chromium Substances 0.000 description 10
- 229950001002 cianidanol Drugs 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 9
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 9
- 229910052804 chromium Inorganic materials 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 235000006468 Thea sinensis Nutrition 0.000 description 8
- 229930003935 flavonoid Natural products 0.000 description 8
- 150000002215 flavonoids Chemical class 0.000 description 8
- 235000017173 flavonoids Nutrition 0.000 description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000037488 Coccoloba pubescens Species 0.000 description 6
- 241000208251 Gymnema Species 0.000 description 6
- 241000545263 Salacia <hydroid> Species 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 6
- 150000007946 flavonol Chemical class 0.000 description 6
- 235000011957 flavonols Nutrition 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 235000009392 Vitis Nutrition 0.000 description 5
- 241000219095 Vitis Species 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 235000020333 oolong tea Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001608472 Bifidobacterium longum Species 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229940009291 bifidobacterium longum Drugs 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960001285 quercetin Drugs 0.000 description 4
- 235000005875 quercetin Nutrition 0.000 description 4
- 235000021283 resveratrol Nutrition 0.000 description 4
- 229940016667 resveratrol Drugs 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 3
- 241000194032 Enterococcus faecalis Species 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000005253 cladding Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000193171 Clostridium butyricum Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 241000134253 Lanka Species 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000013115 immunohistochemical detection Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000011889 obduction Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000009923 sugaring Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000014143 Camellia sinensis var assamica Nutrition 0.000 description 1
- 240000008441 Camellia sinensis var. assamica Species 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 241000208253 Gymnema sylvestre Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000186716 Lactobacillus agilis Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 244000245214 Mentha canadensis Species 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 240000003582 Platycodon grandiflorus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 244000108447 Salacia latifolia Species 0.000 description 1
- 241000051672 Salacia macrosperma Species 0.000 description 1
- 241000051611 Salacia oblonga Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- -1 acetone).Water Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical class C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical group C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
本发明提供了能够调节肠道细菌群落构成比例的食品或药物,其是安全且几乎无副作用。本发明还提供了包含至少一种抑制糖吸收的物质的肠道细菌群落构成比例调节剂、包含所述肠道细菌群落构成比例调节剂的食品或药物。
Description
本申请是申请日为2010年4月21日和申请号为201080017939.9的中国专利申请的分案申请。
技术领域
本发明涉及包含抑制糖吸收的物质的肠道细菌群落构成比例调节剂。
背景技术
根据近期研究,已发现在人类中,肥胖者处于其中拟杆菌门(Bacteroidetes)细菌构成比例低而厚壁菌门(Firmicutes)细菌构成比例高的状态,随着体重下降,拟杆菌门构成比例提高,而相反地,厚壁菌门的构成比例下降。此外,已发现相对于肥胖者,消瘦者具有高的拟杆菌门构成比例和低的厚壁菌门构成比例(参见非专利文献1)。
此外,当肥胖小鼠的肠道细菌群落和正常体重小鼠的肠道细菌群落分别移植至两组不具有肠道细菌的小鼠中时,已发现移植有肥胖小鼠的肠道细菌的该组小鼠的体重比移植有正常体重的小鼠的肠道细菌的该组小鼠的体重显著更大(参见非专利文献2)。
也就是说,通过改变肠道细菌的构成比例,从而改变了体质,并且具有改善身体状况的效果。
厚壁菌门和拟杆菌门的总量接近达到总肠道细菌群落的90%。通过口服物质难以对细菌实现这样大的影响。
对于增殖拟杆菌的方法,已报道有关于摄取低聚果糖(fractooligo saccharide,FOS)的方法,并且可预期一定的效果(参见非专利文献3)。
但是,为了达到摄入低聚果糖的效果,需要大量摄入,并且通过饮食或功能性食品将其摄入给身体造成负担。此外,还未发现具有增殖拟杆菌门所属的细菌,并且还减少厚壁菌门所属的细菌作用的口服物质。
背景技术文献
非专利文献
非专利文献1:Ley,RE.,Turnbaugh,PJ.,Klein,S.和Gordon,JI.,Microbialecology:human gut microbes associated with obesity.Nature,444,1022-3(2006)
非专利文献2:Turnbaugh,PJ.,Ley,RE.,Mahowald,MA.,Magrini,V.,Mardis,ER.和Gordon,JI.,An obesity-associated gut microbiome with increased capacity forenergy harvest.Nature,444,1027-31(2006)
非专利文献3:Nakanishi,Y.,Murashima,K.,Ohara,H.,Suzuki,T.,Hayashi,H.,Sakamoto,M.,Fukasawa,T.,Kubota,H.,Hosono,A.,Kono,T.,Kaminogawa,S.,Benno,Y.,Increase in terminal restriction fragments of Bacteroidetes-derived 16S rRNAgenes after administration of short-chainfructooligosaccharides.Appl.Environ.Microbiol.,72,6271-6(2006)
发明内容
本发明所解决的问题
本发明所解决的问题是提供能够调节肠道细菌群落构成比例的食品或药物,所述食品或药物是安全的,并且几乎没有副作用。
解决所述问题的手段
本发明人首次发现一类具有增殖拟杆菌门细菌并减少厚壁菌门细菌作用的口服物质。
本发明具体包含以下部分。
(1)肠道细菌群落构成比例调节剂,其包含至少一种抑制糖吸收的物质。
(2)根据以上(1)所述的肠道细菌群落构成比例调节剂,其中所述抑制糖吸收的物质是抑制α-葡萄糖苷酶活性的物质。
(3)根据以上(1)或(2)所述的肠道细菌群落构成比例调节剂,其中所述抑制糖吸收的物质包含选自五层龙属(genus Salacia)的植物、桑叶、匙羹藤(Gymnema sylvestre)、以及包含在它们的提取物中的成分中的至少一种或多种。
(4)根据以上(1)-(3)中任一项所述的肠道细菌群落构成比例调节剂,其中所述抑制糖吸收的物质显示出10μg/ml-10000μg/ml的蔗糖酶50%抑制浓度。
(5)根据以上(1)-(4)中任一项所述的肠道细菌群落构成比例调节剂,其中所述抑制糖吸收的物质是选自网状五层龙(Salacia reticulate)、长圆果五层龙(Salaciaoblonga)和中国五层龙(Salacia chinensis)的五层龙属的植物及包含在它们的提取物中的成分中的至少一种。
(6)根据以上(1)-(5)中任一项所述的肠道细菌群落构成比例调节剂,其中所述肠道细菌群落构成比例调节剂提高肠道细菌群落中拟杆菌门(Bacteroidetes)比例,并降低厚壁菌门(Firmicutes)比例。
(7)食品或药品,其包含根据以上(1)-(6)中任一项所述的肠道细菌群落构成比例调节剂。
本发明的有益效果
根据本发明,提供了即使当长期服用时是安全且几乎没有副作用的肠道细菌群落构成比例调节剂、以及食品或药物。通过将其服用,调节了肠道细菌群落平衡,并由此可以瘦身、改善体质、减轻过敏症状、改善免疫指数等。
本发明的实施方式
本发明的肠道细菌群落构成比例调节剂包含至少一种抑制糖吸收的物质。
本发明的肠道细菌群落构成比例调节剂具有改变肠道中生存的细菌比例的作用。特别地,它是具有增加拟杆菌门细菌,并减少厚壁菌门细菌作用的试剂。
<抑制糖吸收的物质>
所述抑制糖吸收的物质优选是抑制α-葡萄糖苷酶活性的物质。
所述抑制α-葡萄糖苷酶活性的物质是通过抑制α-葡萄糖苷酶的活性而抑制糖代谢的物质,并且蔗糖酶50%抑制浓度(IC50值)优选为0.01μg/ml-10000μg/ml,更优选0.1μg/ml-800μg/ml,进一步优选0.5μg/ml-600μg/ml,并且特别优选10μg/ml-450μg/ml。当抑制活性落入所述范围中时,可抑制消化道的葡萄糖吸收的作用,并可抑制腹胀感和气体产生。α-葡萄糖苷酶的蔗糖酶50%抑制浓度更优选为10μg/ml-5000μg/ml,并且进一步优选10μg/ml-2000μg/ml。
通过以下方法测定蔗糖酶50%抑制浓度(IC50值)。
[试验方法1]
蔗糖酶IC50值的测定
样品溶液的制备:将2mg样品(抑制α-葡萄糖苷酶活性的物质)称量入试管中,并向其中加入2mL水,然后使样品完全悬浮以形成浓度为1mg/mL的样品溶液。用水将其稀释以分别形成0、50、100、250和500μg/mL的溶液。
底物溶液的制备:将蔗糖溶于0.2M马来酸盐缓冲液(pH 6.0)中以使蔗糖浓度为100mM,并且将所述溶液用作底物溶液。
粗酶溶液的制备:在将1g大鼠肠道丙酮粉末(intestinal acetone powder rat)(SIGMA制备)悬浮在10mL生理盐水之后,将混悬液进行离心(3000rpm,4℃,5min)。将所得上清液分离出并用作粗酶溶液。
向500μL具有各浓度的上述样品溶液加入400μL所述底物溶液中,并在37℃下将溶液总体在水浴中预热5分钟。向其中加入100μL所述粗酶溶液,并在37℃下进行反应60分钟。在反应完成后,在95℃下通过加热2分钟使所述酶失活以终止反应。使用市售试剂盒/变旋酶-葡萄糖氧化酶方法(Glucose CII Test Wako,Wako Pure Chemical Industries,Ltd.)定量测定所生成的葡萄糖浓度。
空白样的制备:向250μl具有各浓度的上述样品溶液加入200μL所述底物溶液和50μL所述粗酶溶液,并通过在95℃下加热2分钟立即将酶进行加热-失活而得到空白数据。
基于所得值形成校正曲线,并测定酶活性被抑制50%时的浓度(IC50值)。
在设置包含于肠道细菌群落构成比例调节剂中的抑制α-葡萄糖苷酶活性的物质的每日摄入量或标准摄入量的情况中,当使用IC50值为50μg/ml的抑制α-葡萄糖苷酶活性的物质时,肠道细菌群落构成比例调节剂的每日摄入量中的抑制α-葡萄糖苷酶活性的物质的量优选为10-600mg,更优选为40-450mg,并且特别优选为50-350mg。
根据以上的每日优选量可合理计算肠道细菌群落构成比例调节剂中包含的抑制α-葡萄糖苷酶活性的物质量。例如,在制备每日摄入量为3片的片剂的情况中,优选每片包含每日摄入量的三分之一。也就是说,所述片剂包含的抑制α-葡萄糖苷酶活性的物质的量优选为3-200mg,更优选13-150mg,特别优选17-117mg。
此外,由下式1测定的值优选为0.5或更大,更优选0.8或更大,并且特别优选1.7或更大。
作为由式2所确定的值,肠道细菌群落构成比例调节剂的总IC50值优选为0.1-7.5,更优选0.15-4.50,并且特别优选0.3-3.75。
[式1]
肠道细菌群落构成比例调节剂的每日摄入量中的抑制α-葡萄糖苷酶活性的物质(mg)/IC50值(μg/ml)
[式2]
肠道细菌群落构成比例调节剂(mg)/IC50值(μg/ml)
所述抑制糖吸收的物质优选是五层龙属的植物、桑叶、匙羹藤、杜仲叶、番石榴、罗布麻纤维、发酵黑豆提取物、茶叶、厚朴、茵陈蒿(Artemisiae capillaris herba)、陈皮(Ctrus unshiu peel)、吴茱萸(evodia fruit)、薄荷(Japanese mint)、桔梗(Chinesebellflower)、枸杞(Chinese wolfberry fruit)、五味子等及它们的提取物,并且优选是五层龙属的植物、桑叶、匙羹藤及它们的提取物。更优选地,五层龙属的植物提取物、桑叶提取物、或在匙羹藤中包含的组分。
<五层龙属的植物的粉碎物或提取物>
所述抑制糖吸收的物质优选是五层龙属的植物。五层龙属的植物通常包括其粉碎物或提取物。
五层龙属的植物是主要在斯里兰卡、印度和东南亚区域野生的卫矛科植物。更具体地,使用选自网状五层龙(Salacia reticulate)、长圆果五层龙(Salacia oblonga)、五层龙(Salacia prinoides)、中国五层龙(Salacia chinensis)、阔叶五层龙(Salacialatifolia)、河口五层龙(Salacia burunoniana)、粉叶五层龙(Salacia grandiflora)和多籽五层龙(Salacia macrosperma)中的一种或多种植物,并且优选选自网状五层龙、长圆果五层龙和中国五层龙中的至少一种植物。
五层龙属的植物的粉碎物或提取物是指可食用部分如根、茎、叶、花和果的粉碎物、干燥物、提取物、其干燥粉末(提取物粉末)等。混合并使用一种或多种所述部分也是合适的。更优选地,使用从根和茎中提取的提取物粉末。
提取物粉末是从上述可食用部分等通过溶剂提取得到的干燥物。提取溶剂可选自水和醇如甲醇和乙醇、或水和醇或酮(如丙酮)的混合溶剂。优选使用水、醇或含水醇。更优选地,使用热水或乙醇或含水乙醇作为提取溶剂。对于以上含水醇的醇浓度,可使用30-90质量%,优选40-70质量%浓度的含水醇。
对于所述干燥方法,可提及喷雾干燥、冷冻干燥等,但不限于此。
<其它成分>
本发明的肠道细菌群落构成比例调节剂还可包含其它成分,并可包含如乳酸菌、无芽孢酵母、类黄酮、多酚等、以及具有免疫活性作用的口服物质。
在肠道细菌群落构成比例调节剂包含这些成分的情况中,当肠道细菌群落构成比例调节剂是固体时,基于肠道细菌群落构成比例调节剂整体,其含量优选为0.1质量%-30质量%,并且更优选为5质量%-20质量%。当肠道细菌群落构成比例调节剂是液体时,基于肠道细菌群落构成比例调节剂整体,其含量优选为0.001质量%-10质量%,并且更优选为0.01质量%-5质量%。
乳酸菌如双歧杆菌优选是可向包括人类在内的哺乳动物口服给药,并在生命体消化道中表现出有效作用的那些乳酸菌。
更具体地,优选的是那些对宿主无害、对胃酸和胆汁酸相对耐受、固定在生命体肠道内、产生乳酸并具有调节肠道细菌群落构成比例作用的乳酸菌。这样的有效乳酸菌实例包括嗜酸乳杆菌(Lactobacillus acidophilus)、长双歧杆菌(Bifidobacteria(Bifidobacterium longum等))、粪链球菌(Streptococcus faecalis)、罗伊氏乳杆菌(Lactobacillus reuteri)、干酪乳杆菌(Lactobacillus casei)、植物乳杆菌(Lactobacillus plantarum)、发酵乳杆菌(Lactobacillus fermentum)、鼠李糖乳杆菌(Lactobacillus rhamnosus)、能动乳杆菌(Lactobacillus agilis)、戈氏乳杆菌(Lactobacillus gasseri)、马铃薯乳杆菌(Bacillus mesentericus)、酪酸梭菌(Clostridium butyricum)或它们的亚种。优选嗜酸乳杆菌、长双歧杆菌(Bifidobacteriumlongum等)和粪链球菌。可单独使用这些乳酸菌或可合理地组合使用它们中的两种或更多种。
对于这些乳酸菌,对得到它们的来源没有特别限制,只要它们是活菌,并且是可广泛使用的市售乳酸菌。
在设置本发明中所使用的肠道细菌群落构成比例调节剂的每日摄入量或标准摄入量的情况中,肠道细菌群落构成比例调节剂的每日量中乳酸菌的活菌数优选为10,000,000-100,000,000,000,更优选为50,000,000-50,000,000,000,并且特别优选为100,000,000-10,000,000,000。
所述无芽孢酵母是指包含矿物的酵母。对于矿物,可提及被称为微量元素的16种金属元素:钠(Na)、钾(K)、氯(Cl)、钙(Ca)、镁(Mg)、磷(P)和硫(S)、铁(Fe)、锌(Zn)、铜(Cu)、锰(Mn)、钴(Co)、铬(Cr)、碘(I)、钼(Mo)和硒(Se)。对于本发明所使用的无芽孢酵母,优选包含铬的铬酵母。对酵母的种类没有特别限制,但优选酿酒酵母(Saccharomycescerevisiae)或其相关种类,首选面包酵母和啤酒酵母。
铬酵母的铬含量优选为0.01-5质量份,更优选0.05-1质量份,并且特别优选0.1-0.3质量份,其基于100质量份的铬酵母。
在肠道细菌群落构成比例调节剂中的铬酵母含量优选为0.5-50质量份,更优选1-10质量份,并且特别优选3-5质量份,其基于肠道细菌群落构成比例调节剂的质量份。
在设置每日摄入量或标准摄入量时,在肠道细菌群落构成比例调节剂的每日量中的铬酵母量优选为5-500mg,更优选10-100mg,并且特别优选30-50mg。在肠道细菌群落构成比例调节剂的每日量中的铬量优选为20-200μg,更优选40-150μg,并且特别优选60-100μg。
类黄酮是广泛存在于植物的所有器官中的有色物质成分的统称,其主要包含在蔬果中,并且在绿叶和白色蔬菜和柑橘皮中特别地以糖苷形式存在。
在本发明中,类黄酮是广泛包含在植物中的有色物质成分的统称,并且特别是指在蔬果中富含的黄烷衍生物。
对于类黄酮,优选黄酮醇、异黄酮和儿茶素。黄酮醇也被称为多酚。
类黄酮是摄入体内的物质,但其通常难以吸收。但是,由于即使少量的类黄酮也是有效的,并且其是强抗氧剂,所以已知它们有抑制致癌物质活性,并具有促进血液流动的作用和抗血栓形成的作用。
在本发明中,类黄酮可得自各来源物如茶、葡萄和洋葱。在此,所述来源物是指从生命体的至少一部分所提取的产物。对于提取,例如采用制备以上五层龙属的植物提取物的方法。提取物的形式可以和以上相同,并且例如其可以是任意形式,如提取后的过滤物本身,或经浓缩或稀释的形式,或是其干燥粉末的形式或其混合物。
从常青的山茶科树的茶树中制备包含儿茶素的茶叶提取物。对于茶树,使用在印度、斯里兰卡和东南亚种植的Camellia sinensis var.assamica和在中国和日本种植的Camellia sinensis。对于提取,优选使用水、醇或含水醇。更优选地,可将热水或乙醇或含水乙醇用作提取溶剂。对于以上含水醇的醇浓度,可使用浓度为30质量%-90质量%,优选40质量%-70质量%的含水醇。
对于所述干燥方法,可提及喷雾干燥、冷冻干燥等,但并不限于此。
茶提取物包含抗氧化剂物质如多酚类和儿茶素类。优选包含儿茶素、表儿茶素、没食子儿茶素、表没食子儿茶素、儿茶素没食子酸酯、表儿茶素没食子酸酯、没食子儿茶素没食子酸酯或表儿茶素没食子酸酯,并且特别优选表没食子儿茶素。
本发明的肠道细菌群落构成比例调节剂所包含的茶叶提取物的量优选为0.1-40质量%,进一步优选0.5-35质量%,并且特别优选1.0-30质量%。
此外,类黄酮之一的黄酮醇去除活性氧,并显示出抗氧化作用,如抑制动脉硬化和改善血液流动。在黄酮醇中,多酚之一的白藜芦醇作为抗氧化物质而引人注目。白藜芦醇由芪骨架构成,并且富含在葡萄果皮中,所以它也包含在由葡萄制成的红酒中。
在本发明中,优选包含葡萄提取物或酒浓缩物,其包含黄酮醇作为成分。
本发明的肠道细菌群落构成比例调节剂优选包含的葡萄提取物的量为0.1-30质量%,并且进一步优选包含的量为0.1-10质量%。
白藜芦醇具有燃烧脂肪的作用,防止动脉硬化的血管疾病,显示出抗癌作用,还防止DNA因细胞分裂而缩短,并具有与热量限制的情况中相同的延长细胞寿命的作用,所以已认为该化合物作为防止生活习惯相关的疾病的材料具有极佳效果。
本发明的肠道细菌群落构成比例调节剂中的白藜芦醇的含量优选为0.0001-5.00质量%,并且进一步优选为0.001-2.00质量%。
此外,在黄酮醇中,多酚之一的槲皮素作为抗氧化物质而引人注目。槲皮素具有黄烷机构,并且富含在洋葱皮中。
对于槲皮素,已报到了其生理作用,如作为吸收维生素C的载体、抗氧化作用、免疫作用等。此外,已发现槲皮素对于抑制脂肪吸收是有效的,所以已认为该化合物作为防止生活习惯相关的疾病的材料具有极佳效果。
肠道细菌群落构成比例调节剂中的槲皮素含量优选为0.001-15质量%,更优选为0.05-10质量%,并且进一步优选0.1-5.0质量%。
本发明的肠道细菌群落构成比例调节剂优选特别包含的儿茶素量为1-50质量%。对于儿茶素,特别优选源自绿茶的儿茶素。
此外,本发明的肠道细菌群落构成比例调节剂优选包含具有抑制酯酶活性作用的多酚,其量为2-80质量%。对于具有抑制酯酶活性作用的多酚,特别优选来源于乌龙茶,来源于葡萄、来源于苹果、来源于荔枝、来源于松树皮、来源于柑果等的多酚。
具有免疫活性作用的口服物质是指被认为增强免疫功能的物质,如玫瑰花提取物和来源于莲花根的物质。所述来源物是指从生命体中的至少一部分提取的产物。对于提取,例如采用制备以上的五层龙属的植物提取物的方法。提取物的形式可以和以上相同,并且例如其可以是任意形式,如提取后的过滤物本身,或经浓缩或稀释的形式,或是其干燥粉末的形式或其混合物。
<使用/配制方法>
本发明的肠道细菌群落构成比例调节剂针对的是包括人类在内的哺乳动物,并且向哺乳动物口服给药。在此,“肠道的”是指“在消化道中的”,其中,拟杆菌门、厚壁菌门、双歧杆菌目等细菌总是存在,并进行消化/吸收,如人类小肠和大肠。
本发明的肠道细菌群落构成比例调节剂可以是食品(包括饮料)、食品材料、准药物、药物、药物材料或用于准药物的材料。对于其它成分,可列举各种药学或食品卫生可接受的载体作为口服给药剂,例如赋型剂、润滑剂、稳定剂、分散剂、粘结剂、稀释剂、增味剂、甜味剂、调味剂和着色剂。
本发明的肠道细菌群落构成比例调节剂的形式不受特别限制,只要它发挥本发明的优点,并且其实例包括片剂、丸剂、颗粒剂、细颗粒剂、咀嚼药物、胶囊剂(充入硬胶囊或软胶囊中的那些)、液体、可咀嚼药物、饮料等。
其形式可以是其它食品形式。
使用通常在本领域中已知的常规方法可制备这些给药形式。
在片剂、丸剂和颗粒剂的情况中,它们可按需制成常规包覆的剂量形式,如糖衣包覆的、明胶包覆的、肠衣包覆的、薄膜包覆的等。此外,片剂可以是多层片剂如双层片剂。
在本发明的肠道细菌群落构成比例调节剂中,除了以上之外,可适当地加入能够口服摄入的成分如维生素、维生素样物质、蛋白质、氨基酸、油和脂肪、有机酸、碳水化合物、植物来源材料、动物来源材料、微生物、食品添加剂和医用添加剂。
通过摄入本发明的肠道细菌群落构成比例调节剂,预期通过增多在肠道中的拟杆菌门细菌并减少厚壁菌门细菌而减轻体重。此外,通过增多肠道拟杆菌门细菌,通过在集合淋巴小结中捕集拟杆菌门肠道细菌,使得预期减轻过敏症状如花粉过敏和特异性,预防普通感冒,并预防肿瘤(Tsuda,M.,Hosono,A.,Yanagibashi,T.,Hachimura,S.,Hirayama,K.,Itoh,K.,Takahashi,K.,和Kaminogawa,S.,Prior stimulation of antigen-presentingcells with Lactobacillus regulates excessive antigen-specific cytokineresponses in vitro when compared with Bacteroides.Cytotechnology,55,89-101(2007))。
本发明的肠道细菌群落构成比例调节剂即使当长期服用下也是安全的,并且几乎没有副作用。
实施例
以下将参照实施例描述本发明,但本发明并不限于以下的实施例。
在将网状五层龙和长圆果五层龙的根和茎部分粉碎之后,将它们等重量混合,并将通过在98℃下的热水提取步骤得到的液体喷雾干燥,得到五层龙提取粉末1。五层龙提取粉末1的蔗糖酶IC50值为41(μg/ml)。
此外,对于匙羹藤和桑叶提取物,可使用购自K.K.Cross的那些。
此外,对于对比例,使用葡萄糖、猪油和乌龙茶聚合多酚(其通过将Suntory Ltd.生产的黑乌龙茶冷冻干燥,并提取乌龙茶聚合多酚而得到)。此外,对于匙羹藤、桑叶提取物、葡萄糖、猪油和乌龙茶聚合多酚,在所有情况中它们的蔗糖酶50%抑制浓度(IC50值)为800μg/mL或更大。
将这些成分各自溶解在水中用于注射,并以10mg/ml的水溶液进行给药。
(实验例1)
将8周龄的雄性SD大鼠分为7个大鼠组。将以下的肠道细菌群落构成比例调节剂各自溶于水中用于注射,并使用胃饲管(stomach sonde)以相当于20mg/kg/天的量经过1周摄取。通过T-RFLP方法(Nagashima法)分别在摄入前即刻和摄入后即刻测定拟杆菌门和厚壁菌门细菌相对于肠道细菌群落的比例。但是,在实施例1中使用半量(10mg/kg/天)的肠道细菌群落构成比例调节剂。
表1中显示了拟杆菌门和厚壁菌门细菌相对于肠道细菌群落的比例(当将细菌总数作为100%时所得的比例)。
对于该实验例的结果,其表明了所述抑制糖吸收的物质相比于其它食品显著提高了肠道菌群中的拟杆菌门/厚壁菌门比例。
根据上述的非专利文献3,通过低聚果糖得到拟杆菌门细菌增多的增殖效果,但其给药量相对于本发明的情况约为90倍。另一方面,在本发明中,即使以少量也得到拟杆菌门细菌增多的效果,并由此可便于摄取。此外,至今还未发现任何减少厚壁菌门所属的细菌比例的食品,但是最近发现了该食品。
在测试期间,对于所有实施例和对比例的大鼠组,没有发现化学检查值如肝功能和肾功能、以及尸体解剖报告和免疫组织化学检查结果出现异常。
(实验例2)
将使用高脂肪饮食饲育的8周龄雄性SD大鼠(HFD32,CLEA Japan,Inc.)分为7个大鼠组。将以下抑制糖吸收的物质等以40mg/kg/天(实施例5中仅为20mg/kg/天)的量溶于水中用于注射,并使用胃饲管进食30天。检查体重、脂肪重量和血清中的甘油三酯水平的变化。对于对照组,仅给予用水注射。对于抑制糖吸收的物质等,使用与实验例1中相同的那些。
表2大鼠的体重、脂肪重量和血清中的甘油三酯水平的变化
(相对于未进食的情况*P<0.05**P<0.01)
对于所述实验例的结果,所述抑制糖吸收的物质抑制了体重的增加,并显著减轻了脂肪重量和血清中的甘油三酯水平,由此得到瘦身的效果。
此外,对于对比例6中的低聚果糖,尽管发现它对于拟杆菌的增殖是有效的,但是没有得到抑制体重、脂肪重量和血清中的甘油三酯水平增加的瘦身效果。
在测试期间,对于所有实施例和对比例的大鼠组,没有发现化学检查值如肝功能和肾功能、以及尸体解剖报告和免疫组织化学检查结果出现异常。
工业实用性
本发明的肠道细菌群落构成比例调节剂可改变肠道细菌群落的构成比例,特别是可增多拟杆菌门细菌并减少厚壁菌门细菌。由此,可期待瘦身、改善体质、减轻过敏症状、改善免疫指数等。此外,所述调节剂即使当长期服用时也是安全的,并且几乎无副作用,并可用作包括饮料在内的食品和药物。
尽管已详细并参照其特定实施方案对本发明进行描述,但对于本领域技术人员而言,在不背离本发明的精神和范围的情况下可进行各种变化和修改。
本申请基于2009年4月22日提交的日本专利申请2009-104316和2009年5月12日提交的日本专利申请2009-115563,并将它们的内容援引并入本文。
Claims (12)
1.一种体重增加抑制剂,其特征在于,其为含有五层龙属植物的提取物的体重增加抑制剂,利用五层龙属植物的提取物使肠道细菌群落中的拟杆菌门的比例增加,使厚壁菌门的比例减少,对肠道细菌群落构成比例进行调整。
2.根据权利要求1所述的体重增加抑制剂,其中,五层龙属植物的提取物为选自网状五层龙、长圆果五层龙及中国五层龙中的至少一种的提取物。
3.根据权利要求1或2所述的体重增加抑制剂,其中,五层龙属植物的提取物为五层龙属植物的热水提取物。
4.根据权利要求1或2所述的体重增加抑制剂,其中,五层龙属植物的提取物为网状五层龙和长圆果五层龙的混合物的热水提取物,显示出10μg/ml至10000μg/ml的蔗糖酶的50%抑制浓度活性。
5.一种脂肪降低剂,其特征在于,其为含有五层龙属植物的提取物的脂肪降低剂,利用五层龙属植物的提取物使肠道细菌群落中的拟杆菌门的比例增加,使厚壁菌门的比例减少,对肠道细菌群落构成比例进行调整。
6.根据权利要求5所述的脂肪降低剂,其中,五层龙属植物的提取物为选自网状五层龙、长圆果五层龙及中国五层龙中的至少一种的提取物。
7.根据权利要求5或6所述的脂肪降低剂,其中,五层龙属植物的提取物为五层龙属植物的热水提取物。
8.根据权利要求5或6所述的脂肪降低剂,其中,五层龙属植物的提取物为网状五层龙和长圆果五层龙的混合物的热水提取物,显示出10μg/ml至10000μg/ml的蔗糖酶的50%抑制浓度活性。
9.一种瘦身剂,其特征在于,其为含有五层龙属植物的提取物的瘦身剂,利用五层龙属植物的提取物使肠道细菌群落中的拟杆菌门的比例增加,使厚壁菌门的比例减少,对肠道细菌群落构成比例进行调整。
10.根据权利要求9所述的瘦身剂,其中,五层龙属植物的提取物为选自网状五层龙、长圆果五层龙及中国五层龙中的至少一种的提取物。
11.根据权利要求9或10所述的瘦身剂,其中,五层龙属植物的提取物为五层龙属植物的热水提取物。
12.根据权利要求9或10所述的瘦身剂,其中,五层龙属植物的提取物为网状五层龙和长圆果五层龙的混合物的热水提取物,显示出10μg/ml至10000μg/ml的蔗糖酶的50%抑制浓度活性。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-104316 | 2009-04-22 | ||
JP2009104316A JP2010254594A (ja) | 2009-04-22 | 2009-04-22 | 腸内バクテロイデス増殖促進剤 |
JP2009115563 | 2009-05-12 | ||
JP2009-115563 | 2009-05-12 | ||
CN2010800179399A CN102413840A (zh) | 2009-04-22 | 2010-04-21 | 肠道细菌群落构成比例调节剂 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800179399A Division CN102413840A (zh) | 2009-04-22 | 2010-04-21 | 肠道细菌群落构成比例调节剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106176883A true CN106176883A (zh) | 2016-12-07 |
Family
ID=43011153
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610580273.7A Pending CN106176883A (zh) | 2009-04-22 | 2010-04-21 | 肠道细菌群落构成比例调节剂 |
CN2010800179399A Pending CN102413840A (zh) | 2009-04-22 | 2010-04-21 | 肠道细菌群落构成比例调节剂 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800179399A Pending CN102413840A (zh) | 2009-04-22 | 2010-04-21 | 肠道细菌群落构成比例调节剂 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120034322A1 (zh) |
EP (1) | EP2422813A4 (zh) |
KR (2) | KR20160105982A (zh) |
CN (2) | CN106176883A (zh) |
WO (1) | WO2010123037A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6133005B2 (ja) * | 2010-02-25 | 2017-05-24 | 富士フイルム株式会社 | 一次胆汁酸及び二次胆汁酸生成調節剤 |
KR20160078507A (ko) * | 2013-11-19 | 2016-07-04 | 옴니액티브 헬스 테크놀로지스 (캐나다) 리미티드 | 살라시아 조성물, 이들의 투여에 의한 치료방법 및 이들의 제조방법 |
KR102323969B1 (ko) * | 2014-03-21 | 2021-11-09 | (주)아모레퍼시픽 | 후발효차 추출물을 포함하는 조성물 |
MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
CN106994136A (zh) * | 2016-01-26 | 2017-08-01 | 富士胶片株式会社 | 肠内细菌数量抑制剂、食品、及药品 |
EP3449932A4 (en) * | 2016-04-26 | 2019-12-04 | TFK Co., Ltd | AGENT FOR REGULATING THE COMPOSITION RATIO OF BACTERIAL INTESTINAL FLORA, MEDICINE, FOOD, BEVERAGE AND METHOD OF REGULATING THE COMPOSITION RATIO OF BACTERIAL INTESTINAL FLORA |
WO2018043706A1 (ja) * | 2016-09-02 | 2018-03-08 | 富士フイルム株式会社 | 家畜用飼料又は家畜用サプリメント、ラクトバチルス属細菌の増殖促進剤、並びにラクトバチルス属細菌の増殖促進方法 |
US10849938B2 (en) | 2017-09-13 | 2020-12-01 | ZBiotics Company | Gene expression system for probiotic microorganisms |
KR102001240B1 (ko) * | 2017-10-31 | 2019-07-18 | 주식회사 케이바이오랩 | 상엽 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 |
WO2019088643A2 (ko) * | 2017-10-31 | 2019-05-09 | 주식회사 케이바이오랩 | 생약 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 |
WO2019181826A1 (ja) * | 2018-03-23 | 2019-09-26 | ティーエフケイ株式会社 | 化合物、腸内細菌叢構成比率調整剤、医薬品、飲食品、食品添加物、腸内細菌叢構成比率の調整方法及び化合物の製造方法 |
CN111743945A (zh) * | 2019-03-28 | 2020-10-09 | 珠海岐微生物科技有限公司 | 陈皮在调节肠道微生物中的用途 |
CN110915887B (zh) * | 2019-12-03 | 2021-09-14 | 华南农业大学 | 一种复合生物保鲜剂及其应用 |
EP4156973A1 (en) * | 2020-05-25 | 2023-04-05 | Metaceutic Aps | Nutraceutical composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742763A (zh) * | 2005-06-30 | 2006-03-08 | 袁干军 | 五层龙提取物在制备保健品和药品中的应用 |
CN101028320A (zh) * | 2006-12-05 | 2007-09-05 | 广州加德恩医药有限公司 | 一种具有降糖降脂作用的植物药组合物及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11127815A (ja) * | 1997-10-29 | 1999-05-18 | Crescendo Corporation:Kk | ある種のオリゴ糖と微生物発酵茶の組合せによる健康維持 |
US6455573B1 (en) * | 2000-01-07 | 2002-09-24 | Simon Fraser University | Glycosidase inhibitors and methods of synthesizing same |
JP3962532B2 (ja) * | 2000-07-03 | 2007-08-22 | 有限会社 坂本薬草園 | 抗糖尿病剤 |
JP4728469B2 (ja) * | 2000-07-06 | 2011-07-20 | 森下仁丹株式会社 | 抗酸化作用を有する肝保護剤 |
JP2003128571A (ja) * | 2001-10-22 | 2003-05-08 | Matsuura Yakugyo Kk | 糖尿病医薬および健康食品 |
TR200502229T2 (tr) * | 2002-12-20 | 2006-11-21 | Unilever N.V. | Bağırsak sağlığı için siyah çay içeren gıda bileşimleri. |
WO2005023021A1 (ja) * | 2003-09-02 | 2005-03-17 | Bbk Bio Corporation | ダイエット食品 |
JP4370309B2 (ja) * | 2005-03-30 | 2009-11-25 | 哲 渡嘉敷 | 麦若葉ともろみ酢由来の健康補助食品 |
JP4391971B2 (ja) * | 2005-07-27 | 2009-12-24 | 株式会社盛光 | 腸内環境改善作用を有する食品組成物 |
US7553502B2 (en) * | 2007-03-07 | 2009-06-30 | Indena S.P.A. | Formulations of alpha-amylase inhibitors with alpha-glucosidase inhibitors useful in the treatment of diabetes and obesity |
EP2030623A1 (en) * | 2007-08-17 | 2009-03-04 | Nestec S.A. | Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
JP5638180B2 (ja) * | 2007-09-06 | 2014-12-10 | 富士フイルム株式会社 | サラシア属植物の抽出物とフラボノイドを含有する食品 |
JP2009104316A (ja) | 2007-10-22 | 2009-05-14 | Okuma Corp | 回転構造物の位置制御方法 |
JP2009115563A (ja) | 2007-11-05 | 2009-05-28 | Fujitsu Microelectronics Ltd | 半導体集積回路 |
-
2010
- 2010-04-21 KR KR1020167023464A patent/KR20160105982A/ko not_active Application Discontinuation
- 2010-04-21 EP EP10767094.5A patent/EP2422813A4/en not_active Withdrawn
- 2010-04-21 US US13/265,753 patent/US20120034322A1/en not_active Abandoned
- 2010-04-21 CN CN201610580273.7A patent/CN106176883A/zh active Pending
- 2010-04-21 CN CN2010800179399A patent/CN102413840A/zh active Pending
- 2010-04-21 WO PCT/JP2010/057092 patent/WO2010123037A1/ja active Application Filing
- 2010-04-21 KR KR1020117024719A patent/KR20120022795A/ko active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742763A (zh) * | 2005-06-30 | 2006-03-08 | 袁干军 | 五层龙提取物在制备保健品和药品中的应用 |
CN101028320A (zh) * | 2006-12-05 | 2007-09-05 | 广州加德恩医药有限公司 | 一种具有降糖降脂作用的植物药组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
FUMINORI UEDA等: "salasia-zoku shokubutsu(salasia reticulate,salasia oblonga)no chonai kankyo eno sayo", 《DAI 62 KAI JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE TAIKAI KOEN YOSHISHU》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010123037A1 (ja) | 2010-10-28 |
KR20120022795A (ko) | 2012-03-12 |
EP2422813A1 (en) | 2012-02-29 |
KR20160105982A (ko) | 2016-09-08 |
CN102413840A (zh) | 2012-04-11 |
EP2422813A4 (en) | 2014-07-23 |
US20120034322A1 (en) | 2012-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106176883A (zh) | 肠道细菌群落构成比例调节剂 | |
JP2015127340A (ja) | 腸内細菌叢構成比率調整剤 | |
JP5638180B2 (ja) | サラシア属植物の抽出物とフラボノイドを含有する食品 | |
KR102132066B1 (ko) | 차전차피와 흑생강을 함유하는 항산화 및 항비만 조성물, 이를 이용한 제제 및 이의 제조방법 | |
US20110280851A1 (en) | Compositions Comprising Cranberry Extract and Methods of Use Thereof | |
US20200108115A1 (en) | Medicinal composition derived from multiple plant sources for gastrointestinal disorder | |
Bianchi et al. | Ability of a high-total antioxidant capacity diet to increase stool weight and bowel antioxidant status in human subjects | |
KR101155079B1 (ko) | 폴리감마글루탐산과 카테킨 갈레이트를 포함하는 혈당상승 억제 및 비만억제 조성물 | |
JP2010077039A (ja) | 免疫賦活剤または抗アレルギー剤 | |
KR20190002036A (ko) | 블루베리 추출물을 포함하는 장내 유익균의 증식을 위한 프리바이오틱스 및 이의 용도 | |
KR100549089B1 (ko) | 장기능 및 변비 질환 개선용 건강 기능성식품 | |
JP2009215275A (ja) | サラシア属植物を含有する経口用組成物 | |
JP2010254594A (ja) | 腸内バクテロイデス増殖促進剤 | |
US20040175444A1 (en) | Crude drug compositions and the process for preparing them | |
KR100437933B1 (ko) | 변비 및 장기능 개선 효과를 갖는 건강보조식품 및 이의조성물 | |
KR101808808B1 (ko) | 벌나무 및 후박나무 추출물을 함유하는 당뇨병 또는 당뇨합병증 예방 및 치료용 조성물 | |
JP2014080448A (ja) | 腸内バクテロイデス増殖促進剤 | |
KR20200039607A (ko) | 고구마 줄기를 포함하는 장내 미생물 개선용 조성물 | |
WO2020079641A1 (en) | Compositions comprising essential oils and/or hydrolates from plants of italian origin and the use thereof for the treatment of gastrointestinal and genitourinary disorders | |
Gandhi et al. | Bioactive compounds of amaranth (Genus Amaranthus) | |
KR101376629B1 (ko) | 신규한 락토바실러스 아리조넨시스 bcnu 9200 균주 및 이를 유효성분으로 포함하는 생균제 조성물 | |
JP7257665B2 (ja) | 経口組成物 | |
KR20220166593A (ko) | 생약 혼합 추출물의 장내 미생물 환경 개선용 조성물 | |
KR20230106980A (ko) | 질경이 잎 추출물을 유효성분으로 함유하는 변비 예방, 개선 또는 치료용 조성물 | |
Anavkar et al. | Plantago ovata (Isabgol) and Rauvolfia serpentina (Indian Snakeroot) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161207 |
|
WD01 | Invention patent application deemed withdrawn after publication |